Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2015-11-02 Regulatory Filings
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVive Presents Findings Targeting Complex I Deficiency at World Mitochondria Congress
Regulatory Filings Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and announces that NeuroVive Pharmaceutical AB presented preclinical data at a scientific congress. It details research findings, quotes the CSO and CEO regarding program progress, and outlines next steps. This format—a press release announcing scientific or business updates, rather than a formal regulatory filing like a 10-K or a comprehensive quarterly report (IR)—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not focused on financial results (like revenue/EPS) but rather on scientific progress and program updates, it fits best under the general category of corporate news. However, given the options, it is a specific corporate announcement. It is not a transcript (CT), a formal report (10-K, IR), or a proxy statement (DEF 14A). It is a news release announcing scientific progress, which often accompanies or precedes an earnings release, but here it functions as a standalone update. Since there is no specific category for 'Scientific Update' or 'Research Presentation Announcement', and it is a formal announcement released to the public via a news release format, the most appropriate general category for non-standard, timely corporate announcements that aren't strictly financial results or mandatory filings is often 'Regulatory Filings' (RNS) if it doesn't fit elsewhere, or 'Earnings Release' (ER) if it's part of the regular reporting cycle. Given the content is a scientific update presented at a congress, and it is structured as a standard press release, it is closest to an Earnings Release (ER) in terms of being a periodic, non-statutory update, or RNS as a general announcement. Since it is a 'NEWS RELEASE' announcing progress, and not a formal financial report, I will classify it as RNS as the best fit for a general, non-financial regulatory/corporate announcement that doesn't fit the other specific categories, although ER is plausible if this was tied to a quarterly update cycle. Given the strong emphasis on scientific findings and program milestones, RNS (Regulatory Filings/General Announcement) is the safest fallback for a non-financial news release.
2015-11-02 English
NeuroVive siktar på att hitta en väg framåt för bolagets antivirala utveckling efter Arbutus beslut att avsluta preklinisk utveckling av OCB-030
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and is dated 2015-10-28. It announces a specific corporate event: a partner (Arbutus) terminating development of a licensed substance (OCB-030) and the company's subsequent plan to find a new path forward. This is a time-sensitive, material announcement intended for immediate public disclosure, typical of an earnings or corporate update, but it is not a full financial report (10-K, IR) or a transcript (CT). Since it is an announcement regarding corporate strategy and partnership changes, it fits best under the general category for regulatory announcements that aren't strictly financial results or director dealings. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, material press release that doesn't fit a more specific category like ER or DIV, although it contains elements of corporate strategy updates. However, since it is a formal press release announcing a significant business development (licensing termination/strategic pivot), it is a general regulatory disclosure. Given the available codes, RNS (Regulatory Filings) serves as the best general category for non-standard, material press releases.
2015-10-28 Swedish
NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus
Regulatory Filings Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and announces a specific corporate event: the discontinuation of a preclinical program (OCB-030) by a partner (Arbutus) and the company's subsequent plans. This type of immediate, material corporate update, which is not a full financial report (like 10-K or IR), a formal dividend notice, or a management change, typically falls under general regulatory announcements. Since it is a press release announcing a strategic development, and it does not fit the specific definitions for ER (Earnings Release, which focuses on financial results), DIV, MANG, or TAR (M&A), the most appropriate general category for a material, non-financial regulatory announcement is Regulatory Filings (RNS). The document length is short (3384 chars), but it is the primary announcement itself, not an announcement *about* another report, so the RPA rule does not strictly apply here.
2015-10-28 English
NeuroVive stärker sitt team för klinisk utveckling ­- tillsätter doktor Magnus Hansson som Chief Medical Officer
Board/Management Information Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and is dated 2015-10-23. The content announces a significant management change: the appointment of Dr. Magnus Hansson as Chief Medical Officer (CMO). This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in senior management. It is not a full financial report (10-K or IR), an earnings release (ER), or a transcript (CT).
2015-10-23 Swedish
NeuroVive Strengthens Clinical Development Team With Appointment of Dr. Magnus Hansson as Chief Medical Officer
Board/Management Information Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and announces a specific corporate event: the appointment of Dr. Magnus Hansson as Chief Medical Officer, effective January 1, 2016. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). The final line confirms it is a news release published under regulatory requirements, but the content is specifically about management change.
2015-10-23 English
Årsstämma 2016 och valberedningen
Report Publication Announcement Classification · 1% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and is dated October 16, 2015. The primary content discusses the upcoming Annual General Meeting (Årsstämma 2016) scheduled for April 28, including deadlines for shareholder proposals and details about the Nomination Committee (valberedningen) members and their mandate. Since the document is an announcement regarding the procedures and composition related to the Annual General Meeting, it directly relates to the AGM process. This aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the AGM, and this announcement sets the stage for it. It is not the voting results (DVA) or a proxy statement (PSI), but preparatory information for the meeting itself.
2015-10-16 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.